Pharmacogenomic research in South Africa: Lessons learned and future opportunities in the rainbow nation

Current Pharmacogenomics and Personalized Medicine

Volumn 9, Issue 3, 2011, Pages 191-207

  Warnich, Louise ^a   Drögemöller, Britt I ^a   Pepper, Michael S ^b,c   Dandara, Collet ^d   Wright, Galen E B ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b UNIVERSITY OF PRETORIA   (South Africa)

^c UNIVERSITY OF GENEVA   (Switzerland)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Disease burden; ELSI; Genomic technologies; Global health; Personalized medicine; Pharmacogenomics; Population genetic diversity; South Africa

Indexed keywords

ACYLTRANSFERASE; AZATHIOPRINE; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; CODEINE; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; EFAVIRENZ; ERYTHROMYCIN; GLIPIZIDE; GLYCOPROTEIN P; MORPHINE; NEVIRAPINE; RIFAMPICIN; THIOPURINE METHYLTRANSFERASE; TOLBUTAMIDE; WARFARIN;

ABCB 1 GENE; ACQUIRED IMMUNE DEFICIENCY SYNDROME; BLOOD TOXICITY; CYP 2B6 GENE; CYP 2C19 GENE; CYP 2C9 GENE; CYP 2D6 GENE; CYP 3A4 GENE; CYP 3A5 GENE; DRUG METABOLISM; GENE; GENE FREQUENCY; GENETIC VARIABILITY; GEOGRAPHIC DISTRIBUTION; HEALTH PROGRAM; HUMAN; LANGUAGE; LEGAL ASPECT; LIVER TOXICITY; MEDICAL RESEARCH; NAT 1 GENE; NAT 2 GENE; NONHUMAN; PHARMACOGENOMICS; PROTEIN FUNCTION; RESEARCH ETHICS; REVIEW; SLEEP DISORDER; SOCIAL ASPECT; SOUTH AFRICA; TPMT GENE; TUBERCULOSIS; VKORC 1 GENE;

EID: 80052235747     PISSN: 18756921     EISSN: 18756913     Source Type: Journal    
DOI: 10.2174/187569211796957575     Document Type: Review

References (155)

1. The World Bank. South Africa: country brief. Available from: http://web.worldbank.org/WBSITE/EXTERNAL/COUNTRIES/AFRICAEXT/SOUTHAFRICAEXTN/0,menuPK:368086~pagePK:141132~piPK:141107~theSitePK:368057,00.html [Accessed May 23, 2011].
2. Coovadia H, Jewkes R, Barron P, et al. The health and health system of South Africa: historical roots of current public health challenges. Lancet 2009; 374(9692): 817-834.
3. Abdool Karim SS, Churchyard GJ, Abdool Karim Q, et al. HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response. Lancet 2009; 374(9693): 921-933.
4. South African Department of Health. Statistics South Africa: Mid-year population estimates 2010. Available from: http://www.statssa.gov.za/publications/P0302/P03022010.pdf [Accessed May 23, 2011].
5. South Africa Every Death Counts Writing Group, Bradshaw D, Chopra M, et al. Every death counts: use of mortality audit data for decision making to save the lives of mothers, babies, and children in South Africa. Lancet 2008; 371(9620): 1294-1304.
6. Chopra M, Daviaud E, Pattinson R, et al. Saving the lives of South Africa's mothers, babies, and children: can the health system deliver? Lancet 2009; 374(9692): 835-846.
7. Mayosi BM, Flisher AJ, Lalloo UG, et al. The burden of noncommunicable diseases in South Africa. Lancet 2009; 374(9693): 934-947.
8. World Health Organisation. World Health Statistics 2010. Available from: http://www.who.int/whosis/whostat/2010/en/index.html [Accessed May 23, 2011].
9. Johansson I, Ingelman-Sundberg M. Genetic polymorphism and toxicology - with emphasis on cytochrome P450. Toxicol Sci 2011; 120(1): 1-13.
10. Wester K, Jönsson AK, Spigset O, et al. Incidence of fatal adverse drug reactions: a population based study. Br J Clin Pharmacol 2008; 65(4): 573-579.
11. Sim SC, Ingelman-Sundberg M. Pharmacogenomic biomarkers: new tools in current and future drug therapy. Trends Pharmacol Sci 2011; 32(2): 72-81.
12. Mehta U, Durrheim DN, Blockman M, et al. Adverse drug reactions in adult medical inpatients in a South African hospital serving a community with a high HIV/AIDS prevalence: prospective observational study. Br J Clin Pharmacol 2008; 65(3): 396-406.
13. Andrews JR, Shah NS, Gandhi N, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: implications for the HIV epidemic and antiretroviral therapy rollout in South Africa. J Infect Dis 2007; 196(Suppl 3): S482-S490.
14. Werely CJ, Donald PR, van Helden PD. NAT2 polymorphisms and their influence on the pharmacology and toxicity of isoniazid in TB patients. Per Med 2007; 4(2): 123-131.
15. Johnson R, Warren RM, van der Spuy GD, et al. Drug-resistant tuberculosis epidemic in the Western Cape driven by a virulent Beijing genotype strain. Int J Tuberc Lung Dis 2010; 14(1): 119-121.
16. Pang T. Pharmacogenomics and personalized medicine for the developing world - too soon or just-in-time? A personal view from the World Health Organization. Curr Pharmacogenomics Person Med 2009; 7(3): 149-157.
17. Department of Health: Republic of South Africa. The South African antiretroviral treatment guidelines 2010. Available from: http://www.doh.gov.za/docs/factsheets/guidelines/art.pdf. [Accessed May 23, 2011].
18. Orkin C, Sadiq ST, Rice L, et al. Prospective epidemiological study of the prevalence of human leukocyte antigen (HLA)-B*5701 in HIV-1-infected UK subjects. HIV Med 2010; 11(3): 187-192.
19. Munderi P, Snowden WB, Walker AS, et al. Distribution of HLAB alleles in a Ugandan HIV-infected adult population: NORA pharmacogenetic substudy of DART. Trop Med Int Health 2011; 16(2): 200-204.
20. Rotimi CN, Jorde LB. Ancestry and disease in the age of genomic medicine. N Engl J Med 2010; 363(16): 1551-1558.
21. Department: Science and Technology, South Africa. Available from: http://www.dst.gov.za [Accessed May 23, 2011].
22. Hardy BJ, Séguin B, Ramesar R, et al. South Africa: from species cradle to genomic applications. Nat Rev Genet 2008; 9(Suppl 1): S19-S23.
23. Sirugo G, Hennig BJ, Adeyemo AA, et al. Genetic studies of African populations: an overview on disease susceptibility and response to vaccines and therapeutics. Hum Genet 2008; 123(6): 557-598.
24. Jenkins T. Medical genetics in South Africa. J Med Genet 1990; 27(12): 760-779.
25. Patterson N, Petersen DC, van der Ross RE, et al. Genetic structure of a unique admixed population: implications for medical research. Hum Mol Genet 2010; 19(3): 411-419.
26. Cavalli-Sforza LL. Genes, peoples, and languages. Proc Natl Acad Sci USA 1997; 94(15): 7719-7724.
27. Campbell MC, Tishkoff SA. African genetic diversity: implications for human demographic history, modern human origins, and complex disease mapping. Annu Rev Genomics Hum Genet 2008; 9: 403-433.
28. Schuster SC, Miller W, Ratan A, et al. Complete Khoisan and Bantu genomes from southern Africa. Nature 2010; 463(7283): 943-947.
29. Gonder MK, Mortensen HM, Reed FA, et al. Whole-mtDNA genome sequence analysis of ancient African lineages. Mol Biol Evol 2007; 24: 757-768.
30. Schlebusch CM, Naidoo T, Soodyall H. SNaPshot minisequencing to resolve mitochondrial macro-haplogroups found in Africa. Electrophoresis 2009; 30(21): 3657-3664.
31. Naidoo T, Schlebusch CM, Makkan H, et al. Development of a single base extension method to resolve Y chromosome haplogroups in sub-Saharan African populations. Investig Genet 2010; 1(1): 6.
32. Statistics South Africa: census 2001. Available from: http://www.statssa.gov.za/census01/HTML/RSAPrimary.pdf [Accessed May 23, 2011].
33. Lane AB, Soodyall H, Arndt S, et al. Genetic substructure in South African Bantu-speakers: evidence from autosomal DNA and Ychromosome studies. Am J Phys Anthropol 2002; 119(2): 175-185.
34. Tishkoff SA, Reed FA, Friedlaender FR, et al. The genetic structure and history of Africans and African Americans. Science 2009; 324(5930): 1035-1044.
35. Van der Ross RE. Up from slavery: slaves at the Cape, their origins, treatment and contribution. Cape Town: Ampersand Press and University of the Western Cape. 2005.
36. De Wit E, Delport W, Rugamika CE, et al. Genome-wide analysis of the structure of the South African Coloured population in the Western Cape. Hum Genet 2010; 128(2): 145-153.
37. Quintana-Murci L, Harmant C, Quach H, et al. Strong maternal Khoisan contribution to the South African coloured population: a case of gender-biased admixture. Am J Hum Genet 2010; 86(4): 611-620.
38. Soodyall H, Jenkins T. Mitochondrial DNA studies in the South African Indian population. Gene Geogr 1992; 6(3): 127-137.
39. Greeff JM. Deconstructing Jaco: genetic heritage of an Afrikaner. Ann Hum Genet 2007; 71(5): 674-688.
40. Hall D, Wijsman EM, Roos JL, et al. Extended intermarker linkage disequilibrium in the Afrikaners. Genome Res 2002; 12: 956-961.
41. Bajaj M, Banerji MA. Type 2 diabetes in South Asians: a pathophysiologic focus on the Asian-Indian epidemic. Curr Diab Rep 2004; 4: 213-218.
42. Ikediobi O, Aouizerat B, Xiao Y, et al. Analysis of pharmacogenetic traits in two distinct South African populations. Hum Genomics. In press.
43. Sim SC. Home Page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee. Available from: http://www.cypalleles.ki.se/ [Accessed May 23, 2011].
44. Thorn CF, Lamba JK, Lamba V, et al. PharmGKB summary: very important pharmacogene information for CYP2B6. Pharmacogenet Genomics 2010; 20(8): 520-523.
45. Parathyras JB. Molecular genetic analysis of human immunodeficiency virus antiretroviral therapy response in South Africa: a pharmacogenetics study. Master's thesis, Stellenbosch University. 2007. Available from: https://scholar.sun.ac.za/bitstream/handle/10019.1/2638/Parath.pdf?sequence=2 [Accessed May 23, 2011].
46. Parathyras J, Gebhardt S, Hillermann-Rebello R, et al. A pharmacogenetic study of CD4 recovery in response to HIV antiretroviral therapy in two South African population groups. J Hum Genet 2009; 54(5): 261-265.
47. Matimba A, Oluka MN, Ebeshi BU, et al. Establishment of a biobank and pharmacogenetics database of African populations. Eur J Hum Genet 2008; 16(7): 780-783.
48. Gross R, Aplenc R, Tenhave T, et al. Slow efavirenz metabolism genotype is common in Botswana. J Acquir Immune Defic Syndr 2008; 49(3): 336-337.
49. Klein K, Lang T, Saussele T, et al. Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics 2005; 15(12): 861-873.
50. Nyakutira C, Röshammar D, Chigutsa E, et al. High prevalence of the CYP2B6 516G>T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol 2008; 64(4): 357-365.
51. Cohen K, Grant A, Dandara C, et al. Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa. Antivir Ther 2009; 14(5): 687-695.
52. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001; 52(4): 349-355.
53. PharmGKB: vitamin K epoxide reductase complex, subunit 1. Available from: http://www.pharmgkb.org/do/serve?objId=PA133787052&objCls=Gene [Accessed May 23, 2011].
54. Mitchell C, Gregerson N, Krause A. Novel CYP2C9 and VKORC1 gene variants associated with warfarin dosage variability in the South African black population. Pharmacogenomics. In press.
55. Maurice CB, Barua PK, Simses D, et al. Comparison of assay systems for warfarin-related CYP2C9 and VKORC1 genotyping. Clinica Chimica Acta 2010; 411(13-14): 947-954.
56. Matimba A, Del-Favero J, Van Broeckhoven C, et al. Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects. Hum Genomics 2009; 3(2): 169-190.
57. Kudzi W, Dodoo AN, Mills JJ. Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population. BMC Med Genet 2009; 10: 124.
58. Scordo MG, Aklillu E, Yasar U, et al. Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br J Clin Pharmacol 2001; 52(4): 447-450.
59. Allabi AC, Gala JL, Desager JP, et al. Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations. Br J Clin Pharmacol 2003; 56(6): 653-657.
60. Limdi NA, Wadelius M, Cavallari L, et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 2010; 115(18): 3827-3834.
61. Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther 2011; 89(3): 464-467.
62. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009; 302(8): 849-857.
63. Dandara C, Masimirembwa CM, Matimba A, et al. Genetic polymorphism of CYP2D6 and CYP2C19 in east- and southern African populations including psychiatric patients. Eur J Clin Pharmacol 2001; 57(1): 11-17.
64. Drögemöller BI, Wright GE, Niehaus DJ, et al. Characterization of the genetic profile of CYP2C19 in two South African populations. Pharmacogenomics 2010; 11(8): 1095-1103.
65. Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 2010; 121(4): 512-518.
66. Owen RP, Sangkuhl K, Klein TE, et al. Cytochrome P450 2D6. Pharmacogenet Genomics 2009; 19(7): 559-562.
67. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004; 369(1): 23-37.
68. Sistonen J, Sajantila A, Lao O, et al. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics 2007; 17(2): 93-101.
69. Gaedigk A, Coetsee C. The CYP2D6 gene locus in South African Coloureds: unique allele distributions, novel alleles and gene arrangements. Eur J Clin Pharmacol 2008; 64(5): 465-475.
70. Wright GE, Niehaus DJ, Drögemöller BI, et al. Elucidation of CYP2D6 genetic diversity in a unique African population: implications for the future application of pharmacogenetics in the Xhosa population. Ann Hum Genet 2010; 74(4): 340-350.
71. Gaedigk A, Simon SD, Pearce RE, et al. The CYP2D6 activity score: Translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 2008; 83, 234-242.
72. Lamba JK, Lin YS, Schuetz EG, et al. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002; 54(10): 1271-1294.
73. Plant N. The human cytochrome P450 sub-family: transcriptional regulation, inter-individual variation and interaction networks. Biochim Biophys Acta 2007; 1770(3): 478-488.
74. Ingelman-Sundberg M, Sim SC, Gomez A, et al. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007; 116(3): 496-526.
75. Annotated PGx Gene Information for CYP3A4. Available from: http://www.pharmgkb.org/search/annotatedGene/cyp3a4/ [Accessed May 23, 2011].
76. Chelule PK, Gordon M, Palanee T, et al. MDR1 and CYP3A4 polymorphisms among African, Indian, and white populations in KwaZulu-Natal, South Africa. Clin Pharmacol Ther 2003; 74(2): 195-196.
77. Zeigler-Johnson CM, Walker AH, Mancke B, et al. Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4. Hum Hered 2002; 54(1): 13-21.
78. Garsa AA, McLeod HL, Marsh S. CYP3A4 and CYP3A5 genotyping by Pyrosequencing. BMC Med Genet 2005; 6: 19.
79. Kudzi W, Dodoo AN, Mills JJ. Genetic polymorphisms in MDR1, CYP3A4 and CYP3A5 genes in a Ghanaian population: a plausible explanation for altered metabolism of ivermectin in humans? BMC Med Genet 2010; 11: 111.
80. Fernandez P, De Beer PM, Van der Merwe L, et al. Genetic variations in androgen metabolism genes and associations with prostate cancer in South African men. S Afr Med J 2010; 100(11): 741-745.
81. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27(4): 383-391.
82. Rebbeck TR, Jaffe JM, Walker AH, et al. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1998; 90(16): 1225-1229.
83. Dandara C, Li DP, Walther G, et al. Gene-environment interaction: the role of SULT1A1 and CYP3A5 polymorphisms as risk modifiers for squamous cell carcinoma of the oesophagus. Carcinogenesis 2006; 27(4): 791-797.
84. Dandara C, Ballo R, Parker MI. CYP3A5 genotypes and risk of oesophageal cancer in two South African populations. Cancer Lett 2005; 225(2): 275-282.
85. Hodges LM, Markova SM, Chinn LW, et al. Very important pharmacogene summary. Pharmacogenet Genomics 2011; 21(3): 152-161.
86. Aszalos A. Drug-drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1) II. Clinical aspects. Drug Discov Today 2007; 12(19-20): 838-843.
87. Leschziner GD, Andrew T, Pirmohamed M, et al. ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J 2007; 7(3): 154-179.
88. Schaeffeler E, Eichelbaum M, Brinkmann U, et al. Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet 2001; 358(9279): 383-384.
89. Loktionov A, Moore W, Spencer SP, et al. Differences in Nacetylation genotypes between Caucasians and Black South Africans: implications for cancer prevention. Cancer Detect Prev 2002; 26(1): 15-22.
90. Dandara C, Masimirembwa CM, Matimba A, et al. Arylamine Nacetyltransferase (NAT2) genotypes in Africans: the identification of a new allele with nucleotide changes 481C>T and 590G>A. Pharmacogenetics 2003; 13(1): 55-58.
91. Adams CH, Werely CJ, Victor TC, et al. Allele frequencies for glutathione S-transferase and N-acetyltransferase 2 differ in African population groups and may be associated with oesophageal cancer or tuberculosis incidence. Clin Chem Lab Med 2003; 41(4): 600-605.
92. Relling MV, Gardner EE, Sandborn WJ, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther 2011; 89(3): 387-391.
93. Ross CJ, Katzov-Eckert H, Dubé MP, et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet 2009; 41(12): 1345-1349.
94. Heckmann JM, Lambson EM, Little F, et al. Thiopurine methyltransferase (TPMT) heterozygosity and enzyme activity as predictive tests for the development of azathioprine-related adverse events. J Neurol Sci 2005; 231(1-2): 71-80.
95. International HapMap Project. Available from: http://hapmap.ncbi.nlm.nih.gov/ [Accessed May 23, 2011].
96. Haas DW, Bartlett JA, Andersen JW, et al. Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin Infect Dis 2006; 43(6): 783-786.
97. Estrela RC, Ribeiro FS, Carvalho RS, et al. Distribution of ABCB1 polymorphisms among Brazilians: impact of population admixture. Pharmacogenomics 2008; 9(3): 267-276.
98. Rosenberg NA, Huang L, Jewett EM, et al. Genome-wide association studies in diverse populations. Nat Rev Genet 2010; 11(5): 356-366.
99. Iles MM. What can genome-wide association studies tell us about the genetics of common disease? PLoS Genet 2008; 4(2): e33.
100. National Institutes of Health (NIH) Pharmacogenomics Research Network. Available from: www.nigms.nih.gov/Initiatives/PGRN [Accessed May 23, 2011].
101. Hewitt RE. Biobanking: the foundation of personalized medicine. Curr Opin Oncol 2011; 23(1): 112-119.
102. Frayling TM, Timpson NJ, Weedon MN, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 2007; 316(5826): 889-894.
103. Zeggini E, Weedon MN, Lindgren CM, et al. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 2007; 316(5829): 1336-1341.
104. Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. Nature 2009; 461(7265): 747-753.
105. 1000 Genomes Project Consortium, Durbin RM, Abecasis GR, et al. A map of human genome variation from population-scale sequencing. Nature 2010; 467(7319): 1061-1073.
106. International HapMap 3 Consortium, Altshuler DM, Gibbs RA, et al. Integrating common and rare genetic variation in diverse human populations. Nature 2010; 467(7311): 52-58.
107. Ashley EA, Butte AJ, Wheeler MT, et al. Clinical assessment incorporating a personal genome. Lancet 2010; 375(9725): 1525-1535.
108. Day-Williams AG, Zeggini E. The effect of next-generation sequencing technology on complex trait research. Eur J Clin Invest 2011; 41(5), 561-567.
109. Thorn CF, Whirl-Carrillo M, Klein TE, et al. Pathway-based approaches to pharmacogenomics. Curr Pharmacogenomics 2007; 5: 79-86.
110. Ozdemir V, Husereau D, Hyland S, et al. Personalized medicine beyond genomics: new technologies, global health diplomacy and anticipatory governance. Curr Pharmacogenomics Person Med 2009; 7 (4): 225-230.
111. Nyika A. Ethical and practical challenges surrounding genetic and genomic research in developing countries. Acta Trop 2009; 112(Suppl 1): S21-S31.
112. Ilkilic I, Paul NW. Ethical aspects of genome diversity research: genome research into cultural diversity or cultural diversity in genome research? Med Health Care Philos 2009; 12(1): 25-34.
113. Mkhize N. A primer: Doing research in traditional cultures. 2005. Available from: http://humansubjects.energy.gov/doe-resources/newsletter/Summer05.pdf [Accessed May 23, 2011].
114. Cook CT. Sangomas: problem or solution for South Africa's health care system. J Natl Med Assoc 2009; 101(3): 261-265.
115. Peltzer K, Mngqundaniso N, Petros G. A controlled study of an HIV/AIDS/STI/TB intervention with traditional healers in KwaZulu-Natal, South Africa. AIDS Behav 2006; 10(6): 683-690.
116. Nyika A, Chilengi R, Ishengoma D, et al. Engaging diverse communities participating in clinical trials: case examples from across Africa. Malar J 2010; 9: 86.
117. Malaria Genomic Epidemiology Network. A global network for investigating the genomic epidemiology of malaria. Nature 2008; 456(7223): 732-737.
118. National Health Act No. 61 of 2003. Available from: http://www.info.gov.za/view/DownloadFileAction?id=68039 [Accessed May 23, 2011].
119. Slabbert MN, Pepper MS. "A room of our own?" Legal lacunae regarding genomic sovereignty in South Africa. Tydskrif vir Hedendaagse Romeins-Hollandse Reg 2010; 73: 432-450.
120. Puoane T, Steyn K, Bradshaw D, et al. Obesity in South Africa: the South African demographic and health survey. Obes Res 2002; 10(10): 1038-1048.
121. Bradshaw D, Norman R, Pieterse D, et al. Estimating the burden of disease attributable to diabetes in South Africa in 2000. S Afr Med J 2007; 97(8 Pt 2): 700-706.
122. Norman R, Bradshaw D, Steyn K, et al. Estimating the burden of disease attributable to high cholesterol in South Africa in 2000. S Afr Med J 2007; 97(8 Pt 2): 708-715.
123. Olckers A, Towers GW, van der Merwe A, et al. Protective effect against type 2 diabetes mellitus identified within the ACDC gene in a black South African diabetic cohort. Metabolism 2007; 56 (5): 587-592.
124. Steyn K, Bradshaw D, Norman R, et al. Determinants and treatment of hypertension in South Africans: the first Demographic and Health Survey. S Afr Med J 2008; 98(5): 376-380.
125. Ndebele PAC, Musesengwa RB. Will developing countries benefit from their participation in genetics research? Malawi Med J 2008; 20(2): 67-69.
126. Schüklenk U, Kleinsmidt A. North-south benefit sharing arrangements in bioprospecting and genetic research: A critical ethical and legal analysis. Dev World Bioeth 2006; 6(3): 122-134.
127. National Environmental Management: Biodiversity Act No. 10 of 2004. Available from: http://www.info.gov.za/gazette/acts/2004/a10-04.pdf [Accessed May 23, 2011].
128. Human Tissue Act No. 65 of 1983. Available from: http://www.enviroleg.co.za/acts/Human%20Tissue/Human%20Tissue%20Act.pdf [Accessed May 23, 2011].
129. Kuhn L, Schramm DB, Donninger S, et al. African infants' CCL3 gene copies influence perinatal HIV transmission in the absence of maternal nevirapine. AIDS 2007; 21(13): 1753-1761.
130. Violari A, Cotton MF, Gibb DM et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008; 359(21): 2233-2244.
131. Roberts L, Passmore JA, Williamson C, et al. Plasma cytokine levels during acute HIV-1 infection predict HIV disease progression. AIDS 2010; 24(6): 819-831.
132. Asselman V, Thienemann F, Pepper DJ, et al. Central nervous system disorders after starting antiretroviral therapy in South Africa. AIDS 2010; 24(18): 2871-2876.
133. Möller M, Nebel A, Valentonyte R, et al. Investigation of chromosome 17 candidate genes in susceptibility to TB in a South African population. Tuberculosis (Edinb) 2009; 89(2): 189-194.
134. Kagina BM, Abel B, Scriba TJ, et al. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns. Am J Respir Crit Care Med 2010; 182(8): 1073-1079.
135. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010; 362(8): 697-706.
136. Van Loggerenberg F, Mlisana K, Williamson C, et al. Establishing a cohort at high risk of HIV infection in South Africa: Challenges and experiences of the CAPRISA 002 acute infection study. PLoS ONE 2008; 3(4): e1954.
137. Cornell M, Technau K, Fairall L, et al. Monitoring the South African National Antiretroviral Treatment Programme, 2003-2007: the IeDEA Southern Africa collaboration. S Afr Med J 2009; 99(9): 653-660.
138. Stingl JC, Brockmöller J. Why, when, and how should pharmacogenetics be applied in clinical studies? Current and future approaches to study designs. Clin Pharmacol Ther 2011; 89(2): 198-209.
139. Warren RM, Streicher EM, Gey van Pittius NC, et al. The clinical relevance of Mycobacterial pharmacogenetics. Tuberculosis (Edinb) 2009; 89(3): 199-202.
140. World Health Organization: Cancer fact sheet N°297. February 2011. Available from: http://www.who.int/mediacentre/factsheets/fs297/en/ [Accessed May 23, 2011].
141. FDA. Table of pharmacogenomic biomarkers in drug labels. Available from: http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm [Accessed May 23, 2011].
142. EMA: Reflection paper on pharmacogenomics in oncology. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003866.pdf [Accessed May 23, 2011].
143. Abdelhak S, Adebamowo C, Adeyemo A, et al. Harnessing genomic technologies toward improving health in Africa: opportunities and challenges. Available from: http://h3africa.org/h3africa_whitepaper.pdf [Accessed May 23, 2011].
144. De Vré R, Verde ER, da Silva JS. Pharmaceuticals & medical products practice: Closing the R&D gap in African health care. McKinsey quarterly. June 2010: 1-8.
145. DST supports southern African human genome initiative. Available from: http://medical.bizcommunity.com/Article/196/148/55072.html [Accessed May 23, 2011].
146. PGENI. Available from: http://pgeni.unc.edu/ [Accessed May 23, 2011].
147. Chirac P, Torreele E. Global framework on essential health R&D. Lancet 2006; 367(9522): 1560-1561.
148. Lévesque E, Leclerc D, Puymirat J, et al. Developing registries of volunteers: key principles to manage issues regarding personal information protection. J Med Ethics 2010; 36(11): 712-714.
149. Human Proteome Project. Available from: http://www.hupo.org/research/hpp/ [Accessed May 23, 2011].
150. Janssens AC, Ioannidis JP, van Duijn CM, et al. Strengthening the reporting of Genetic Risk Prediction Studies: The GRIPS statement. Genet Med 2011; 13(5), 453-456.
151. Khoury MJ, Gwinn M, Yoon PW et al. The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet Med 2007; 9(10): 665-674.
152. Pathmasiri S, Deschênes M, Joly Y, et al. Intellectual property rights in publicly funded biobanks: much ado about nothing? Nat Biotechnol 2011; 29(4): 319-323.
153. Wynne B. Public engagement as a means of restoring public trust in science--hitting the notes, but missing the music? Community Genet 2006; 9(3): 211-220.
154. Lehoux P. Moving beyond our mutual ignorance. Or, how would engaging the public benefit the personalized medicine community? Curr Pharmacogenomics Person Med 2011; 9(1): 76-79.
155. Schicktanz S, Schweda M, Wynne B. The ethics of 'public understanding of ethics'-why and how bioethics expertise should include public and patients' voices. Med Health Care Philos 2011 Mar 30. [Epub ahead of print].